Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: acoramidis hydrochloride, revusiran, eplontersen +10 | 1.00 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 48 Parkinson's papers of 6,754 | 0.49 |
| pathways Reactome | 6 pathways; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 6635
Sealed predictions
- TTR in dopamine neurons, braak+0.37 (p 0.329) → +0.22 (p 0.570)receipt 6642
Swarm cases
receipt 6642: TTR in dopamine neurons, braak
- power
- full sample +0.18 (p 0.465, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.20 (p 0.434, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.02 (p 0.942, n 18). could be the mix.
- skeptic
- leave-one-out range +0.10 to +0.33, sign flips 0; without severely affected donors +0.18 (p 0.465, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TTR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts